AngioSoma, Inc. (OTC Pink: SOAN) is a health and wellness company that is focused on the research & development of supplements across nutraceuticals, cosmeceuticals, and pharmaceuticals. Shares of the health company skyrocketed 255%, during trading on Monday, May 14, 2018. Over the past month, AngioSoma, Inc. has seen average daily volume of 8,934 shares. However, volume of 7.46 million shares or dollar volume of $373,000, exchanged hands on Monday.
Shares of AngioSoma, Inc. soared today after the company announced that that its flagship pharmaceutical product, Liprostin, has received a grant of patent notification from the U.S. Patent Office. Liprostin is developed to treat Peripheral Artery Disease (PAD). The company has already completed Clinical Trials I and II (a, b, and c) and is prepared to begin the final third round of trials needed before commercialization. Here is the full press release detailing of the grant of patent:
AngioSoma, Inc. Press Release:
HOUSTON, TX, May 14, 2018 (GLOBE NEWSWIRE) — AngioSoma, Inc. (OTC: SOAN) is excited to announce that the U.S. Patent Office has agreed to grant our patent application for our flagship pharmaceutical, Liprostin™ that is intended to treat Peripheral Artery Disease, or PAD.
We are told the market opportunity is significant with 8 million U.S. diagnosed cases of PAD costing $212 – $389 billion annually. PAD costs exceed diabetes, coronary artery disease and cancers. It is reported that 60% to 70% of diabetics contract peripheral artery disease, often resulting in amputation as treatment.
Clinical Trials I, and II a-b-c have shown that Liprostin™ is effective for treating walking pain and circulation. However, the third clinical trial must be successfully completed before Liprostin™ may be commercialized.
A past director and significant stockholder has proposed that we reassign the patent and related technology to our founder and affiliate. We are considering his proposal.
Nutraceuticals include StemStrength™, an all-natural stimulant for accelerated muscle and tissue development, and RockOn™, a potent libido complex tonic for male and female usage, containing popular ingredients for sexual health.
Our cosmeceuticals include three products:
Rapid Wrinkle Reducer™: a skin-smoothing serum gentle enough for everyday use. Instant results from plant extracts help reduce the appearance of fine lines and wrinkles and help to combat the appearance of aging skin.
Powerful Peptide Eye Serum™: helps to reduce the appearance of eye bags, dark circles, and puffy eyes by relieving the accumulation of fluids and increasing the firmness around your eyes.
Collagen Anti-Aging Crème™: nourishes and protects skin while encouraging skin cell renewal. It supports elastin and collagen production, which promotes skin moisture, elasticity, and thickness. It also has a healing effect on troubled or damaged skin areas.
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (http://www.angiosoma.com), a Nevada corporation based in Houston, Texas, markets our Somaceuticals™ line of health supplements. Our innovative supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals, all dedicated to improving the mental and physical wellbeing of men and women. Alex Blankenship, CEO, has expressed her appreciation for the valuable contribution of AllianceTek, for developing the marketing strategy as well as the design and creation of our marketing website: www.soma-ceuticals.com.